Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084965 | 0.89 | KDM4C (0.61) | NSD2KDM4CKDM5BHSD11B1CNR1 | |
| SCHEMBL4562976 | 0.88 | KDM4C (0.51) | NSD2KDM4CKDM5AKDM5BHSD11B1 | |
| SCHEMBL4085411 | 0.88 | KDM4C (0.57) | NSD2KDM4CKDM5AKDM5BHSD11B1 | |
| SCHEMBL4085395 | 0.82 | MAPK14 (0.58) | NSD2KDM4CKDM5AKDM5B | |
| SCHEMBL4076257 | 0.81 | DPP4 (0.49) | NSD2HSD11B1CNR1OPRL1DPP4 | |
| SCHEMBL4076134 | 0.73 | OPRL1 (0.38) | NSD2HSD11B1CNR1OPRL1 | |
| SCHEMBL4076136 | 0.73 | OPRL1 (0.40) | CNR1OPRL1 | |
| SCHEMBL4075928 | 0.72 | DPP4 (0.49) | HSD11B1OPRL1DPP4DPP8 | |
| Cyclohexane Carboxamide SCHEMBL27759599 | 0.72 | CNR1 (0.52) | KDM4CCNR1OPRL1 | |
| SCHEMBL19465343 | 0.72 | KDM5A (0.46) | KDM4CKDM5AKDM5BHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | FONG TUNG M (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1482794-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | Merck & Co., Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003075660-A1 | METHOD OF TREATMENT OR PREVENTION OF OBESITY | MERCK & CO., INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | NSD2 2527/4885KDM4C 3003/4885KDM5A 2455/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | NSD2 2527/4885KDM4C 3003/4885KDM5A 2455/4885 |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | CNR1, HSD11B1, HSD17B1 | NSD2 1604/4885KDM4C 3666/4885KDM5A 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.